-
Are biopharmaceutical companies "out of favor"?
Time of Update: 2021-12-07
Since the second half of this year, there has been frequent news of Hillhouse reducing its holdings in the pharmaceutical outsourcing industry: On August 25, Hillhouse withdrew from Tigermed’s top ten
-
Treadwell Therapeutics released a report at the 2021 SITC (Society for Cancer Immunotherapy) annual meeting, introducing the clinical application of the first HPK1 inhibitor CFI-402411 of its kind.
Time of Update: 2021-12-07
Hematopoietic progenitor kinase 1 (HPK1) has a negative regulatory effect on immune cell activation, and CFI-402411 is the first oral inhibitor of its kind against HPK1 .
-
The scale of the Chinese medicine market continues to expand, and high-quality development becomes the top priority of pharmaceutical companies
Time of Update: 2021-12-07
According to this trend, the industry predicts that the market size of China's traditional Chinese medicine industry will maintain a compound annual growth rate of about 14% in the next few years.
-
The official release of an important signal, the third round of national mining has come?
Time of Update: 2021-12-07
The "Notice" mentioned that in order to reduce repetitive operations and improve work efficiency, relevant companies have completed information maintenance in the Henan, Jinxi, Jiangxi, Hubei, Chongqing, Guizhou, Yunnan, Guining, Qingxiang and Hebei orthopedic trauma medical consumables procurement project led by Henan Province.
-
Industry: starting next year, the golden age of the pharmaceutical sector will restart
Time of Update: 2021-12-07
China Merchants Fund believes that under the situation of a high base last year, the performance of pharmaceutical companies in the third quarter has clearly differentiated, and it is expected that the trend of differentiation will continue in the market outlook .
-
Gan Lai announced that the farnesol X receptor agonist ASC42 for the treatment of primary biliary cholangitis Phase II and III clinical trial protocol was approved by the China National Food and Drug Administration
Time of Update: 2021-12-07
Based on the Phase II and Phase III clinical trial protocol of ASC42 for the treatment of PBC approved by the National Food and Drug Administration of China, Gan Lai will conduct phase II clinical trials in 100 patients with insufficient or intolerance to ursodeoxycholic acid (UDCA).
-
Paragraph 4!
Time of Update: 2021-12-07
This is an open, single-arm, multi-center study aimed at evaluating the safety, tolerability, pharmacokinetic characteristics, and effectiveness of ICP-189 single-agent and combination therapy in patients with advanced solid tumors .
-
With the continuous upgrading of the traditional Chinese medicine formula granule industry, pharmaceutical companies are facing stricter supervision
Time of Update: 2021-12-07
In addition, since November 1st, the Hebei Provincial Drug Administration, the Provincial Administration of Traditional Chinese Medicine, the Provincial Health Commission, and the Provincial Medical Insurance Bureau jointly issued the "Hebei Province Traditional Chinese Medicine Formula Granule Management Implementation Rules (Trial)" has also been officially implemented .
-
From November 15th to November 16th, a collection of important announcements in the pharmaceutical industry
Time of Update: 2021-12-07
On November 15th, Sinopharm Hyundai issued an announcement that the company's holding subsidiary Sinopharm Yixin Received the “Approval Notice of Drug Supplement Application” for Octreotide Acetate Injection approved and issued by the National Food and Drug Administration, and approved the drug to pass the generic drug quality and efficacy consistency evaluation .
-
The world’s first solid tumor CAR-T to obtain PRIME qualification, Keji Pharmaceutical’s CT041 was granted priority medicine (PRIME) qualification by the European Medicines Agency (EMA)
Time of Update: 2021-12-07
So far, Keji Pharmaceuticals has become the only company in the world that has two CAR-T products included in the PRIME plan .
Keji Pharmaceutical's mission is to'cure tumors', and through continuous technological innovation, we will strive to develop better therapeutic drugs for cancer patients around the world .
-
RedHill announces that related trials have completed randomization of patients
Time of Update: 2021-12-07
Part A of the Phase 2/3 study for patients with new coronary pneumonia who have developed symptoms but do not require hospitalization by oral administration of RHB-107 (upamostat) once a day has compl
-
Ruike Biotechnology obtained the New Crown Vaccine "Drug Production License" issued by the Jiangsu Provincial Food and Drug Administration
Time of Update: 2021-12-07
The new crown vaccine and adjuvant production base established by Ruike Biotech in Taizhou, Jiangsu Province is constructed in accordance with the current international GMP standards.
-
The two pharmaceutical companies have reached a major cooperation, the tens of billions of long-acting growth hormone market may face changes
Time of Update: 2021-12-07
On November 11, Jichuan Pharmaceutical issued an announcement, announcing that it had reached a strategic cooperation in product development, production and commercialization with Tianjing Bio on long-acting recombinant human growth hormone (Yitan) .
-
110 medical device products have been approved and registered by the State Food and Drug Administration
Time of Update: 2021-12-07
On November 15, the State Drug Administration issued an announcement stating that in October 2021, the State Drug Administration approved and registered 110 medical device products .
-
Recently, 29 batches of drugs failed to pass the random inspection
Time of Update: 2021-12-07
On November 10, the Guangdong Provincial Food and Drug Administration issued the "Notice on Drug Sampling Inspection Information (No.
On the same day, the Food and Drug Administration of Guangdong Province also issued a notice on drug sampling inspection information.
-
Wantai Bio-Nose Spray Covid-19 Vaccine Receives South Africa Phase Ⅲ Clinical Trial Approval
Time of Update: 2021-12-07
Recently, the nasal spray influenza virus carrier new crown pneumonia vaccine ("nasal spray new crown vaccine") developed by it in cooperation with Xiamen University and the University of Hong Kong has won Phase III issued by the South African Drug Administration.
-
AZ over $1 billion injections, Hausen will be approved for Huiyu's new entry
Time of Update: 2021-12-07
Figure 3: Enterprise competitive landscape of 2021H1 Fulvestrant injection Source: Mi Nei. com, China's public medical institutions terminal competition pattern CP Tianqing Pharmaceutical Group submitted 4 types of generic listing applications in 2019, and was approved for the first imitation + first review in August 2020.
-
Medical insurance negotiations have ended, and the industry recommends focusing on investment opportunities in this area
Time of Update: 2021-12-07
In the case of more and more standardized clinical drug management, innovative drugs that enter the medical insurance catalog are expected to quickly achieve commercialization, which is especially good for business.
-
Advanced Sterilization Products leader raises medical infection prevention standards in Asia
Time of Update: 2021-12-07
Nilesh Shah, Vice President, General Manager and Global Business Leader of Advanced Sterilization Products (ASP)After successfully responsible for the sale of ASP from Johnson & Johnson to Fortive (as the parent company) in 2019, Nilesh expanded ASP to emerging markets in Asia, providing infection prevention technologies and workflow solutions for healthcare facilities to improve efficiency and productivity .
-
AstraZeneca structure adjustment!
Time of Update: 2021-12-07
On November 15th, AstraZeneca China officially announced to employees that some of the business structure has been adjusted, and the main changes are in the two core sectors: Jixian Business and Cardiovascular As for the metabolism and kidney business, the following two specific adjustments have been made:Division of Hexian Business: Hexian Oncology Business was merged into Oncology Division, and non-oncology business was independent, becoming Jixian Chronic Disease Business Department .
